Wells Fargo Keeps Their Buy Rating on Becton Dickinson (BDX)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Becton Dickinson (BDXResearch Report) on July 9. The company’s shares closed yesterday at $256.17.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 17.0% and a 73.6% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies Inc, Shockwave Medical Inc, and Baxter International.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Becton Dickinson with a $277 average price target, representing an 8.1% upside. In a report issued on June 28, Raymond James also maintained a Buy rating on the stock with a $288 price target.

See today’s analyst top recommended stocks >>

Becton Dickinson’s market cap is currently $69.1B and has a P/E ratio of 76.01. The company has a Price to Book ratio of 3.24.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.